Ko, J J <br/><br/>
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.  [electronic resource] 

 -  British journal of cancer  Apr 2014 
 - 1917-22 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2014.25  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Renal Cell--drug therapy<br/>Clinical Trials as Topic<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Neoplasm Metastasis<br/>Proportional Hazards Models<br/>Survival Analysis<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors